Announced
Completed
Financials
Tags
cancer therapeutics
Biotechnology
Majority
Domestic
Friendly
oncology
United States
cancer treatment
Public
Acquisition
Single Bidder
Completed
Synopsis
Bristol Myers Squibb, a global biopharmaceutical company, completed the acquisition of Mirati Therapeutics, a commercial stage biotechnology company, for $4.7bn. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond. Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’. We welcome them and look forward to working together to leverage BMS’ global scale and resources to deliver more treatments for cancer patients, faster," Chris Boerner, Bristol Myers CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.